China's National Medical Products Administration accepted Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) marketing application for Likang Kepan fumarate (HRS-5965), according to a Shanghai bourse filing on Tuesday.
The drug was developed as a treatment for patients with paroxysmal nocturnal hemoglobinuria who remain anemic after previous treatment with C5 complement inhibitors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.